TCM
BEAM icon

Tygh Capital Management’s Beam Therapeutics BEAM Stock Holding History

Tygh Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$1.82M Sell
22,899
-44
-0.2% -$3.77K 0.23% 79
2021
Q3 		$2M Buy
+22,943
New +$2.3M 0.27% 84

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Tygh Capital Management's BEAM Position: Q4 2021 in Review

Tygh Capital Management reduced its Beam Therapeutics (BEAM) stake by 0.19% in Q4 2021, selling an estimated $3.77K and leaving 22,899 shares worth $1.82M. The position accounts for 0.23% of the portfolio, ranked #79.

Tygh Capital Management first reported a position in BEAM in Q3 2021 and has held it in 2 quarters since. The position peaked at $2M in Q3 2021. 232 funds tracked by Wall St. Rank hold BEAM as of Q4 2021.

  • Tygh Capital Management held 22,899 shares of Beam Therapeutics worth $1.82M as of Q4 2021.
  • Tygh Capital Management sold 44 Beam Therapeutics shares in Q4 2021, an estimated $3.77K.
  • Beam Therapeutics made up 0.23% of Tygh Capital Management's portfolio in Q4 2021, its #79 holding.
  • Tygh Capital Management first reported a position in Beam Therapeutics in Q3 2021 and has held it in 2 quarters since.
  • Tygh Capital Management's Beam Therapeutics position peaked at $2M in Q3 2021.
  • 232 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2021.

Based on Tygh Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.